176 related articles for article (PubMed ID: 15557777)
1. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
[TBL] [Abstract][Full Text] [Related]
4. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
5. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner HS; Shaw LM
J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
[TBL] [Abstract][Full Text] [Related]
6. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
7. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
[TBL] [Abstract][Full Text] [Related]
8. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
9. Human pharmacokinetics of WR-2721.
Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
11. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
12. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
14. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
[TBL] [Abstract][Full Text] [Related]
15. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
16. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
17. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
Shaw LM; Bonner HS; Brown DQ
Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS.
Simon ES; Reyna D; Lister RJ; Harteg C; Lipka E
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Mar; 1080():82-89. PubMed ID: 29482122
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Anné PR; Curran WJ
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
Li C; Wang S; Huang T; Chen N; Ou M
Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]